Abdul Rehman

Dr. Abdul Rehman


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
Shakta Mani SatyamShakta Mani Satyam
Shakta Mani Satyam
SRSyed Arman Rabbani
Syed Arman Rabbani
YEYahia El-Tanani
Yahia El-Tanani
Alaa A. A. AljabaliAlaa A. A. Aljabali
Alaa A. A. Aljabali
ARAbdul Rehman
Abdul Rehman
Recent progress in material science has led to the development of new drug delivery systems that go beyond the conventional approaches and offer greater accuracy and convenience in the application of therapeutic agents. This review discusses the evolutionary role of nanocarriers, hydrogels, and bioresponsive polymers that offer enhanced drug release, target accuracy, and bioavailability. Oncology, chronic disease management, and vaccine delivery are some of the applications explored in this paper to show how these materials improve the therapeutic results, counteract multidrug resistance, and allow for sustained and localized treatments. The review also discusses the translational barriers of bringing advanced materials into the clinical setting, which include issues of biocompatibility, scalability, and regulatory approval. Methods to overcome these challenges include surface modifications to reduce immunogenicity, scalable production methods such as microfluidics, and the harmonization of regulatory systems. In addition, the convergence of artificial intelligence (AI) and machine learning (ML) is opening new frontiers in material science and personalized medicine. These technologies allow for predictive modeling and real-time adjustments to optimize drug delivery to the needs of individual patients. The use of advanced materials can also be applied to rare and underserved diseases; thus, new strategies in gene therapy, orphan drugs development, and global vaccine distribution may offer new hopes for millions of patients.

1 March 2014 in Translational Research
Verified
Journal Article
Closed access
KJKiseok Jang
Kiseok Jang
HAHyein Ahn
Hyein Ahn
JSJongmin Sim
Jongmin Sim
HHHulin Han
Hulin Han
ARAbdul Rehman
Abdul Rehman
SJSe Jin Jang
Se Jin Jang

27 March 2018 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
ARAbdul Rehman
Abdul Rehman
YKYeseul Kim
Yeseul Kim
HKHyunsung Kim
Hyunsung Kim
JSJongmin Sim
Jongmin Sim
HAHyein Ahn
Hyein Ahn
KJKiseok Jang
Kiseok Jang
Aims: Forkhead box O (FOXO) transcription factors, consisting of FOXO1, FOXO3a, FOXO4 and FOXO6, are involved in carcinogenesis and tumour progression. Recent studies have suggested that FOXOs act as tumour suppressors in a variety of human cancers. This study investigated the clinicopathological significance of FOXOs in triple-negative breast cancer (TNBC). Methods: FOXO protein expressions were assessed by immunohistochemistry in 125 TNBC tissues. Correlations between FOXO protein expression and various clinicopathological parameters, including patients’ survival, were investigated. MDA-MB-468 cell line was used for in vitro cell proliferation and migration assay. Results: FOXO1 protein expression was not observed in all 125 TNBC tissues. FOXO4 and FOXO6 protein expressions were detected in 11 (8.8%) and 14 (11.2%) TNBC tissues, respectively. Loss of FOXO4 expression was significantly associated with high histological grade (P=0.014, χ 2 test), and TNBCs with positive FOXO6 expression correlated with high grade (P=0.020, χ 2 test). FOXO3a expression was detected in 40 (32%) TNBC cases and correlated with adverse clinicopathological features, such as lymph node metastasis (P=0.021, χ 2 test), perineural invasion (P=0.013, χ 2 test) and higher Ki-67 proliferation index (P=0.048, t-test). Additionally, FOXO3a expression was significantly associated with poor disease-free survival (P=0.015, log-rank test). In the in vitro study, siRNA-mediated FOXO3a knockdown in the MDA-MB-468 cell line inhibited cell proliferation and migration. Conclusion: Among FOXO members, FOXO3a may have a potential role in promoting tumour cell migration and proliferation and may serve as a prognostic biomarker and a potential therapeutic target for TNBC.

21 January 2018 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
HAHyein Ahn
Hyein Ahn
HKHyunsung Kim
Hyunsung Kim
ARAbdul Rehman
Abdul Rehman
YKYesul Kim
Yesul Kim
JSJongmin Sim
Jongmin Sim
KJKiseok Jang
Kiseok Jang
Recent research has demonstrated that forkhead box O3a (FoxO3a) may function as an oncogenic transcription factor. We sought to validate the clinicopathologic significance of FoxO3a expression in hepatocellular carcinoma (HCC). Western blotting and immunohistochemistry were used to determine FoxO3a expression. In vitro cell proliferation and migration assays were performed in a HepG2 cell line. FoxO3a was overexpressed in 121 (64.71%) cases of HCC. FoxO3a overexpression was associated with aggressive phenotypes of HCC, such as histologic grade (P < .001), stage (P = .031), and small vessel invasion (P < .001). FoxO3a overexpression was also correlated with poor disease-free survival in both univariate and multivariate survival analyses (P = .001 and P = .018, respectively). Downregulation of FoxO3a in a HepG2 cell line inhibited cell proliferation and migration. These results suggest a role for FoxO3a in HCC progression and support the potential use as a prognostic biomarker.

1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HAHyein Ahn
Hyein Ahn
JSJongmin Sim
Jongmin Sim
ARAbdul Rehman
Abdul Rehman
MCMin Sung Chung
Min Sung Chung
Seung Sam PaikSeung Sam Paik
Seung Sam Paik
KJKiseok Jang
Kiseok Jang
Ahn H, et al. J Korean Med Sci. 2015 Apr;30(4):390-397. https://doi.org/10.3346/jkms.2015.30.4.390

1 January 2015 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
HKHyunsung Kim
Hyunsung Kim
SJSe Min Jang
Se Min Jang
HAHyein Ahn
Hyein Ahn
JSJongmin Sim
Jongmin Sim
KYKijong Yi
Kijong Yi
Seung Sam PaikSeung Sam Paik
Seung Sam Paik
Kim H, et al. J Breast Cancer. 2015 Mar;18(1):1-7. https://doi.org/10.4048/jbc.2015.18.1.1